The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Combination Immunosuppressive Therapy after Factor VIII Infusion for Acquired Factor VIII Inhibitor

Eric C-Y. Lian, MD; Alberto F. Larcada, MD; and Aidan Y-Z. Chiu, MD
[+] Article, Author, and Disclosure Information

Grant Support: Partial support by grant MC-B-12001 from the Bureau of Health Services, grant RO1HL27007 from the National Institutes of Health, grant RR05363 from Biomedical Research, and the Veterans Administration.

Requests for Reprints: Eric C-Y. Lian, MD, Miami Comprehensive Hemophilia Center, University of Miami School of Medicine, P.O. Box 016960 (R7), Miami, FL 33101.

Current Author Addresses: Drs. Lian and Chiu: Miami Comprehensive Hemophilia Center, University of Miami School of Medicine, P.O. Box 016960 (R7), Miami, FL 33101.

Dr. Larcada: 7231 SW 63rd Avenue, Miami, FL 33143.

Ann Intern Med. 1989;110(10):774-778. doi:10.7326/0003-4819-110-10-774
Text Size: A A A

Study Objective: To evaluate the effectiveness of combined cyclophosphamide, vincristine, and prednisone (CVP) therapy after antigenic stimulation with factor VIII in the eradication of factor VIII inhibitor.

Design: Factor VIII activity and inhibitor titer were measured before and after FVIII-CVP therapy and patients with factor VIII inhibitor were followed for at least 2 years.

Setting: The first course of therapy was carried out in the hospital when nonhemophiliac patients were admitted for bleeding. Otherwise, treatment was administered at the outpatient clinic.

Patients: From 1975 to 1986 we studied 12 nonhemophiliac and 5 hemophiliac patients with factor VIII inhibitor treated with FVIII-CVP and followed at our clinic.

Intervention: Patients were infused with one dose of factor VIII concentrate, 50 to 100 U/kg body weight, followed by cyclophosphamide, 500 mg on day 1 and 200 mg/d on days 2 to 5; vincristine, 2 mg on day 1; and prednisone, 100 mg/d on days 1 to 5. This regimen was repeated every 3 to 4 weeks.

Results: Of 12 nonhemophiliac patients, 11 responded after 1 to 3 courses of FVIII-CVP with complete disappearance of the inhibitor without recurrence. Among 5 patients with hemophilia who were given 3 to 8 courses, only 1 patient responded with a transient disappearance of inhibitor. Mild neutropenia and infection occurred in 3 patients and required antibiotic treatment.

Conclusion: Factor VIII-CVP therapy is highly effective in the eradication of factor VIII inhibitor in nonhemophiliac patients but not in patients with hemophilia.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.